Cell-penetrating peptide conjugates to enhance the antitumor effect of paclitaxel on drug-resistant lung cancer

References

• Chen Z, Zhang P, Cheetham AG, et al. (2014). Controlled release of free doxorubicin from peptide-drug conjugates by drug loading. J Control Release 191:123–30
   PubMed Web of Science ®Google Scholar
• Chi KN, Higano C, Reeves J, et al. (2014). A randomized phase III study comparing first line docetaxel and prednisone (DP) to DP plus custirsen in men with metastatic castration resistant prostate cancer. Ann Oncol 25:255–79
   Google Scholar
• Christie RJ, Findley DJ, Grainger DW. (2004). Design and synthesis of a new polymer drug delivery conjugate. Biomed Sci Instrum 40:136–41
   PubMedGoogle Scholar
• De Hoon JP, Veeck J, Vriens BE, et al. (2012). Taxane resistance in breast cancer: a closed HER2 circuit? Biochim Biophys Acta 1825:197–206
   PubMed Web of Science ®Google Scholar
• De La Torre BG, Hornillos V, Luque-Ortega JR, et al. (2014). A BODIPY-embedding miltefosine analog linked to cell-penetrating Tat(48–60) peptide favors intracellular delivery and visualization of the antiparasitic drug. Amino Acids 46:1047–58
   PubMed Web of Science ®Google Scholar
• Farkhani SM, Valizadeh A, Karami H, et al. (2014). Cell penetrating peptides: efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules. Peptides 57:78–94
   PubMed Web of Science ®Google Scholar
• Ferrara R, Pilotto S, Peretti U, et al. (2016). Tubulin inhibitors in non-small cell lung cancer: looking back and forward. Expert Opin Pharmacother 17:1113–29
   PubMed Web of Science ®Google Scholar
• Flores ML, Castilla C, Avila R, et al. (2011). Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction. Breast Cancer Res Treat 133:917–28
   PubMed Web of Science ®Google Scholar
• Fonseca SB, Pereira MP, Kelley SO. (2009). Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev 61:953–64
   PubMed Web of Science ®Google Scholar
• Galletti E, Magnani M, Renzulli ML, Botta M. (2007). Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem 2:920–42
   PubMed Web of Science ®Google Scholar
• Ganem NJ, Storchova Z, Pellman D. (2007). Tetraploidy, aneuploidy and cancer. Curr Opin Genet Dev 17:157–62
   PubMed Web of Science ®Google Scholar
• Gao Y, Kuang Y, Guo Z, et al. (2009). Enzyme-instructed molecular self-assembly confers nanofibers and a supramolecular hydrogel of taxol derivative. J Am Chem Soc 131:13576–7
   PubMed Web of Science ®Google Scholar
• Gu G, Hu Q, Feng X, et al. (2014). PEG-PLA nanoparticles modified with APTEDB peptide for enhanced anti-angiogenic and anti-glioma therapy. Biomaterials 35:8215–26
   PubMed Web of Science ®Google Scholar
• Guo Z, Peng H, Kang J, Sun D. (2016). Cell-penetrating peptides: possible transduction mechanisms and therapeutic applications. Biomed Rep 4:528–34
   PubMed Web of Science ®Google Scholar
• Han M, Vakili MR, Soleymani Abyaneh H, et al. (2014). Mitochondrial delivery of doxorubicin via triphenylphosphine modification for overcoming drug resistance in MDA-MB-435/DOX cells. Mol Pharm 11:2640–9
   PubMed Web of Science ®Google Scholar
• Jelinek M, Balusikova K, Schmiedlova M, et al. (2015). The role of individual caspases in cell death induction by taxanes in breast cancer cells. Cancer Cell Int 15:8
   PubMed Web of Science ®Google Scholar
• Jiang L, Li L, He X, et al. (2015). Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response. Biomaterials 52:126–39
   PubMed Web of Science ®Google Scholar
• Kawamoto S, Takasu M, Miyakawa T, et al. (2011). Inverted micelle formation of cell-penetrating peptide studied by coarse-grained simulation: importance of attractive force between cell-penetrating peptides and lipid head group. J Chem Phys 134:095103
   PubMed Web of Science ®Google Scholar
• Khandare JJ, Jayant S, Singh A, et al. (2006). Dendrimer versus linear conjugate:  influence of polymeric architecture on the delivery and anticancer effect of paclitaxel. Bioconjug Chem 17:1464–72
   PubMed Web of Science ®Google Scholar
• Kibria G, Hatakeyama H, Harashima H. (2014). Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system. Arch Pharm Res 37:4–15
   PubMed Web of Science ®Google Scholar
• Lee J-Y, Choi Y-S, Suh J-S, et al. (2011). Cell-penetrating chitosan/doxorubicin/TAT conjugates for efficient cancer therapy. Int J Cancer 128:2470–80
   PubMed Web of Science ®Google Scholar
• Li F, Wang Z, Huang Y, et al. (2015). Delivery of PUMA apoptosis gene using polyethyleneimine-SMCC-TAT/DNA nanoparticles: biophysical characterization and in vitro transfection into malignant melanoma cells. J Biomed Nanotechnol 11:1776–82
   PubMed Web of Science ®Google Scholar
• Li J, Huang P, Chang L, et al. (2013). Tumor targeting and pH-responsive polyelectrolyte complex nanoparticles based on hyaluronic acid-paclitaxel conjugates and Chitosan for oral delivery of paclitaxel. Macromol Res 21:1331–7
   Web of Science ®Google Scholar
• Liang JF, Yang VC. (2005). Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity. Bioorg Med Chem Lett 15:5071–5
   PubMed Web of Science ®Google Scholar
• Liang L, Lin SW, Dai W, et al. (2012). Novel cathepsin B-sensitive paclitaxel conjugate: higher water solubility, better efficacy and lower toxicity. J Control Release 160:618–29
   PubMed Web of Science ®Google Scholar
• Luo S, Gu Y, Zhang Y, et al. (2015). Precise ratiometric control of dual drugs through a single macromolecule for combination therapy. Mol Pharm 12:2318–27
   PubMed Web of Science ®Google Scholar
• Luqmani YA. (2005). Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 14:35–48
   PubMed Web of Science ®Google Scholar
• Meng S, Su B, Li W, et al. (2011). Integrin-targeted paclitaxel nanoliposomes for tumor therapy. Med Oncol 28:1180–7
   PubMed Web of Science ®Google Scholar
• Minko T, Rodriguez-Rodriguez L, Pozharov V. (2013). Nanotechnology approaches for personalized treatment of multidrug resistant cancers. Adv Drug Deliv Rev 65:1880–95
   PubMed Web of Science ®Google Scholar
• Murakami M, Ernsting MJ, Undzys E, et al. (2013). Docetaxel conjugate nanoparticles that target alpha-smooth muscle actin-expressing stromal cells suppress breast cancer metastasis. Cancer Res 73:4862–71
   PubMed Web of Science ®Google Scholar
• Nakase I, Konishi Y, Ueda M, et al. (2012). Accumulation of arginine-rich cell-penetrating peptides in tumors and the potential for anticancer drug delivery in vivo. J Control Release 159:181–8
   PubMed Web of Science ®Google Scholar
• Nicholson DW. (2000). From bench to clinic with apoptosis-based therapeutic agents. Nature 407:810–16
   PubMed Web of Science ®Google Scholar
• Ogden A, Rida PC, Knudsen BS, et al. (2015). Docetaxel-induced polyploidization may underlie chemoresistance and disease relapse. Cancer Lett 367:89–92
   PubMed Web of Science ®Google Scholar
• Pan Z-Z, Wang H-Y, Zhang M, et al. (2016). Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer. Acta Pharmacol Sin 37:1110–120
   PubMed Web of Science ®Google Scholar
• Park J, Ryu J, Kim K-A, et al. (2002). Mutational analysis of a human immunodeficiency virus type 1 Tat protein transduction domain which is required for delivery of an exogenous protein into mammalian cells. J Gen Virol 83:1173–81
   PubMed Web of Science ®Google Scholar
• Patel NR, Pattni BS, Abouzeid AH, Torchilin VP. (2013). Nanopreparations to overcome multidrug resistance in cancer. Adv Drug Deliv Rev 65:1748–62
   PubMed Web of Science ®Google Scholar
• Patil Y, Sadhukha T, Ma L, Panyam J. (2009). Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release 136:21–9
   PubMed Web of Science ®Google Scholar
• Pawar VK, Panchal SB, Singh Y, et al. (2014). Immunotherapeutic vitamin E nanoemulsion synergies the antiproliferative activity of paclitaxel in breast cancer cells via modulating Th1 and Th2 immune response. J Control Release 196:295–306
   PubMed Web of Science ®Google Scholar
• Puig PE, Guilly MN, Bouchot A, et al. (2008). Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy. Cell Biol Int 32:1031–43
   PubMed Web of Science ®Google Scholar
• Pusztai L, Wagner P, Ibrahim N, et al. (2005). Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104:682–91
   PubMed Web of Science ®Google Scholar
• Rasco DW, Yan J, Xie Y, et al. (2010). Looking beyond surveillance, epidemiology and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population. J Thorac Oncol 5:1529–35
   PubMed Web of Science ®Google Scholar
• Regina A, Demeule M, Che C, et al. (2008). Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol 155:185–97
   PubMed Web of Science ®Google Scholar
• Safavy A, Georg GI, Velde DV, et al. (2004). Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure. Bioconjug Chem 15:1264–74
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. (2012). Cancer statistics, 2012. CA Cancer J Clin 62:10–29
   PubMed Web of Science ®Google Scholar
• Song J, Zhang Y, Zhang W, et al. (2015). Cell penetrating peptide TAT can kill cancer cells via membrane disruption after attachment of camptothecin. Peptides 63:143–9
   PubMed Web of Science ®Google Scholar
• Song XR, Cai Z, Zheng Y, et al. (2009). Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci 37:300–5
   PubMed Web of Science ®Google Scholar
• Soudy R, Chen C, Kaur K. (2013). Novel peptide–doxorubucin conjugates for targeting breast cancer cells including the multidrug resistant cells. J Med Chem 56:7564–73
   PubMed Web of Science ®Google Scholar
• Susa M, Iyer AK, Ryu K, et al. (2009). Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma. BMC Cancer 9:399
   PubMed Web of Science ®Google Scholar
• Szabo I, Orban E, Schlosser G, et al. (2016). Cell-penetrating conjugates of pentaglutamylated methotrexate as potential anticancer drugs against resistant tumor cells. Eur J Med Chem 115:361–8
   PubMed Web of Science ®Google Scholar
• Teow HM, Zhou Z, Najlah M, et al. (2013). Delivery of paclitaxel across cellular barriers using a dendrimer-based nanocarrier. Int J Pharm 441:701–11
   PubMed Web of Science ®Google Scholar
• Tian XP, Qian D, He LR, et al. (2014). The telomere/telomerase binding factor PinX1 regulates paclitaxel sensitivity depending on spindle assembly checkpoint in human cervical squamous cell carcinomas. Cancer Lett 353:104–14
   PubMed Web of Science ®Google Scholar
• Topham CH, Taylor SS. (2013). Mitosis and apoptosis: how is the balance set? Curr Opin Cell Biol 25:780–5
   PubMed Web of Science ®Google Scholar
• Tseng Y-L, Liu J-J, Hong R-L. (2002). Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. Mol Pharmacol 62:864–72
   PubMed Web of Science ®Google Scholar
• Van Bracht E, Versteegden LR, Stolle S, et al. (2014). Enhanced cellular uptake of albumin-based lyophilisomes when functionalized with cell-penetrating peptide TAT in HeLa cells. PLoS One 9:1–9
   Web of Science ®Google Scholar
• van Zuylen L, Nooter K, Sparreboom A, Verweij J. (2000). Development of multidrug-resistance convertors: sense or nonsense? Invest New Drugs 18:205–20
   PubMed Web of Science ®Google Scholar
• Vargas JR, Stanzl EG, Teng NN, Wender PA. (2014). Cell-penetrating, guanidinium-rich molecular transporters for overcoming efflux-mediated multidrug resistance. Mol Pharm 11:2553–65
   PubMed Web of Science ®Google Scholar
• Vasile E, Tibaldi C, Leon GL, et al. (2015). Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients. J Cancer Res Clin Oncol 141:1189–94
   PubMed Web of Science ®Google Scholar
• Wang C, Ma Y, Feng S, et al. (2015a). Gonadotropin-releasing hormone receptor-targeted paclitaxel-degarelix conjugate: synthesis and in vitro evaluation. J Pept Sci 21:569–76
   PubMed Web of Science ®Google Scholar
• Wang F, Wang Y-C, Dou S, et al. (2011). Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano 5:3679–92
   PubMed Web of Science ®Google Scholar
• Wang S, Qiu J, Shi Z, et al. (2015b). Nanoscale drug delivery for taxanes based on the mechanism of multidrug resistance of cancer. Biotechnol Adv 33:224–41
   PubMed Web of Science ®Google Scholar
• Wei B, Wei Y, Zhang K, et al. (2009). Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell-penetrating peptide. Biomed Pharmacother 63:313–18
   PubMed Web of Science ®Google Scholar
• Xia H, Gao X, Gu G, et al. (2011). Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration. Biomaterials 32:9888–98
   PubMed Web of Science ®Google Scholar
• Xia H, Gu G, Hu Q, et al. (2013). Activatable cell penetrating peptide-conjugated nanoparticles with enhanced permeability for site-specific targeting delivery of anticancer drug. Bioconjug Chem 24:419–30
   PubMed Web of Science ®Google Scholar
• Xu Y, Asghar S, Li H, et al. (2016). Preparation of a paclitaxel-loaded cationic nanoemulsome and its biodistribution via direct intratumoral injection. Colloids Surf B Biointerfaces 142:81–8
   PubMed Web of Science ®Google Scholar
• Yusuf RZ, Duan Z, Lamendola DE. (2003). Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3:1–19
   PubMed Web of Science ®Google Scholar
• Zhang P, Cheetham AG, Lock LL, Cui H. (2013). Cellular uptake and cytotoxicity of drug-peptide conjugates regulated by conjugation site. Bioconjug Chem 24:604–13
   PubMed Web of Science ®Google Scholar
• Zhong J, Li L, Zhu X, et al. (2015). A smart polymeric platform for multistage nucleus-targeted anticancer drug delivery. Biomaterials 65:43–55
   PubMed Web of Science ®Google Scholar
• Zhou W, Xu J, Gelston E, et al. (2015). Inhibition of Bcl-xL overcomes polyploidy resistance and leads to apoptotic cell death in acute myeloid leukemia cells. Oncotarget 6:21557–71
   PubMed Web of Science ®Google Scholar
• Zunino F, Capranico G. (1990). DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Anti-Cancer Drug Des 5:307–17
   PubMedGoogle Scholar
• Zuo KQ, Zhang XP, Zou J, et al. (2010). Establishment of a paclitaxel resistant human breast cancer cell strain (MCF-7/Taxol) and intracellular paclitaxel binding protein analysis. J Int Med Res 38:1428–35
   PubMed Web of Science ®Google Scholar